Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.

Leukemia Research
G J MadlambayanC R Cogle

Abstract

Some oncolytic viruses, such as myxoma virus (MYXV), can selectively target malignant hematopoietic cells, while sparing normal hematopoietic cells. This capacity for discrimination creates an opportunity to use oncolytic viruses as ex vivo purging agents of autologous hematopoietic cell grafts in patients with hematologic malignancies. However, the mechanisms by which oncolytic viruses select malignant hematopoietic cells are poorly understood. In this study, we investigated how MYXV specifically targets human AML cells. MYXV prevented chloroma formation and bone marrow engraftment of two human AML cell lines, KG-1 and THP-1. The reduction in human leukemia engraftment after ex vivo MYXV treatment was dose-dependent and required a minimum MOI of 3. Both AML cell lines demonstrated MYXV binding to leukemia cell membranes following co-incubation: however, evidence of productive MYXV infection was observed only in THP-1 cells. This observation, that KG-1 can be targeted in vivo even in the absence of in vitro permissive viral infection, contrasts with the current understanding of oncolytic virotherapy, which assumes that virus infection and productive replication is a requirement. Preventing MYXV binding to AML cells with heparin...Continue Reading

References

Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
Oct 24, 2002·Blood·Tommy AlainAnna E Kossakowska
Mar 15, 2003·Blood·Chandini M ThirukkumaranDonald G Morris
Nov 19, 2005·Nature Reviews. Cancer·Kelley A ParatoJohn C Bell
Feb 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Elizabeth Kelly, Stephen J Russell
Mar 10, 2007·Current Cancer Drug Targets·Wang Yu, Hu Fang
Mar 30, 2007·British Journal of Haematology·Gough G AuDarren R Shafren
Apr 24, 2007·Bone Marrow Transplantation·C M ThirukkumaranD G Morris
Jun 17, 2008·Nature Reviews. Microbiology·Roberto CattaneoMichael A Barry
Dec 24, 2008·Nature Reviews. Cancer·David H Kirn, Steve H Thorne
Mar 10, 2010·Cytokine & Growth Factor Reviews·Masmudur M RahmanGrant McFadden
Aug 25, 2010·Pediatric Blood & Cancer·Adrienne M HammillTimothy P Cripe

❮ Previous
Next ❯

Citations

Oct 2, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jonathan G PolBrian D Lichty
Jun 4, 2013·Vaccine·Winnie M ChanGrant McFadden
Feb 24, 2016·Experimental Hematology·Raphael C BosseChristopher R Cogle
Jul 3, 2019·Journal for Immunotherapy of Cancer·Louise M E MüllerFiona Errington-Mais
Jan 16, 2020·Journal of Clinical Medicine·Masmudur M Rahman, Grant McFadden
Mar 12, 2021·Current Oncology·Vanessa InnaoAlessandro Allegra
Apr 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric BarteeGrant McFadden

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.